Alzheimer's disease pathology: pathways between chronic vascular risk factors and blood-brain barrier dysfunction in a cohort of patients with different types of dementia

被引:13
作者
Gan, Jinghuan [1 ]
Yang, Xia [1 ]
Zhang, Guili [2 ,3 ]
Li, Xudong [2 ,3 ]
Liu, Shuai [4 ]
Zhang, Wei [2 ,3 ]
Ji, Yong [4 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, Dept Cognit Disorder, Beijing, Peoples R China
[3] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[4] Tianjin Huanhu Hosp, Tianjin Dementia Inst, Dept Neurol, Tianjin Key Lab Cerebrovasc & Neurodegenerat Dis, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
blood-brain barrier; Qalb; Alzheimer's disease; dementia; diabetes mellitus; FRONTOTEMPORAL LOBAR DEGENERATION; CEREBRAL MICROBLEEDS; TIGHT JUNCTIONS; PERMEABILITY; DISRUPTION; DIAGNOSIS; BREAKDOWN; INTEGRITY; RATIO; HYPERTENSION;
D O I
10.3389/fnagi.2023.1088140
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
BackgroundBlood brain barrier (BBB) breakdown is considered a potential mechanism of dementia. The Alzheimer's disease (AD) biomarkers and vascular factors are also associated with BBB permeability. ObjectiveIn the present study, the combination effects of neuropathological biomarkers of AD and chronic vascular risk factors for BBB were investigated. MethodsThe cerebrospinal fluid (CSF)/serum albumin ratio (Qalb), an indicator of BBB permeability, was measured in a total of 95 hospitalized dementia patients. The demographics, clinical information, and laboratory tests were collected from the inpatient records. The CSF neuropathological biomarkers of AD and apolipoprotein E (APOE) genotype were also collected. The mediation analysis model was used to calculate the associations among neuropathological biomarkers of AD (mediator), the Qalb, and chronic vascular risk factors. ResultsThree types of dementia, AD (n = 52), Lewy body dementia (LBD, n = 19), and frontotemporal lobar degeneration (n = 24), were included with a mean Qalb of 7.18 (+/- 4.36). The Qalb was significantly higher in dementia patients with type 2 diabetes mellitus (T2DM, p = 0.004) but did not differ based on the presence of APOE epsilon 4 allele, CMBs, or amyloid/tau/neurodegeneration (ATN) framework. The Qalb was negatively associated with the levels of A beta 1-42 (B = -20.775, p = 0.009) and A beta 1-40 (B = -305.417, p = 0.005) and positively associated with the presence of T2DM (B = 3.382, p < 0.001) and the levels of glycosylated hemoglobin (GHb, B = 1.163, p < 0.001) and fasting blood glucose (FBG, B = 1.443, p < 0.001). GHb is a direct chronic vascular risk factor for higher Qalb (total effect B = 1.135, 95% CI: 0.611-1.659, p < 0.001). Ratios of A beta 1-42/A beta 1-40 or t-tau/A beta 1-42 were mediators of the association between the Qalb and GHb; the direct effect of GHb on the Qalb was 1.178 (95% CI: 0.662-1.694, p < 0.001). ConclusionGlucose exposure can directly or indirectly affect BBB integrity through A beta and tau, indicating glucose affects BBB breakdown and glucose stability plays an important role in dementia protection and management.
引用
收藏
页数:15
相关论文
共 75 条
[1]   Occipital blood-brain barrier permeability is an independent predictor of visual outcome in type 2 diabetes, irrespective of the retinal barrier: A longitudinal study [J].
Abuhaiba, S. I. ;
Cordeiro, M. ;
Amorim, A. ;
Cruz, A. ;
Quendera, B. ;
Ferreira, C. ;
Ribeiro, L. ;
Bernardes, R. ;
Castelo-Branco, M. .
JOURNAL OF NEUROENDOCRINOLOGY, 2018, 30 (01)
[2]   The blood-brain barrier as an endocrine tissue [J].
Banks, William A. .
NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (08) :444-455
[3]   Apolipoprotein E controls cerebrovascular integrity via cyclophilin A [J].
Bell, Robert D. ;
Winkler, Ethan A. ;
Singh, Itender ;
Sagare, Abhay P. ;
Deane, Rashid ;
Wu, Zhenhua ;
Holtzman, David M. ;
Betsholtz, Christer ;
Armulik, Annika ;
Sallstrom, Jan ;
Berk, Bradford C. ;
Zlokovic, Berislav V. .
NATURE, 2012, 485 (7399) :512-516
[4]   Lack of Widespread BBB Disruption in Alzheimer's Disease Models: Focus on Therapeutic Antibodies [J].
Bien-Ly, Nga ;
Boswell, C. Andrew ;
Jeet, Surinder ;
Beach, Thomas G. ;
Hoyte, Kwame ;
Luk, Wilman ;
Shihadeh, Vera ;
Ulufatu, Sheila ;
Foreman, Oded ;
Lu, Yanmei ;
DeVoss, Jason ;
van der Brug, Marcel ;
Watts, Ryan J. .
NEURON, 2015, 88 (02) :289-297
[5]   Amyloid-β Interacts with Blood-Brain Barrier Function in Dementia: A Systematic Review [J].
Burgmans, Saartje ;
de Haar, Harm J. van ;
Verhey, Frans R. J. ;
Backes, Walter H. .
JOURNAL OF ALZHEIMERS DISEASE, 2013, 35 (04) :859-873
[6]   Valsartan alleviates the blood-brain barrier dysfunction in db/db diabetic mice [J].
Cai, Longxue ;
Li, Wenfeng ;
Zeng, Renqing ;
Cao, Zuohong ;
Guo, Qicai ;
Huang, Qi ;
Liu, Xianfa .
BIOENGINEERED, 2021, 12 (01) :9070-9080
[7]   Role of Blood-Brain Barrier in Alzheimer's Disease [J].
Cai, Zhiyou ;
Qiao, Pei-Feng ;
Wan, Cheng-Qun ;
Cai, Min ;
Zhou, Nan-Kai ;
Li, Qin .
JOURNAL OF ALZHEIMERS DISEASE, 2018, 63 (04) :1223-1234
[8]   Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient [J].
Castellazzi, Massimiliano ;
Morotti, Andrea ;
Tamborino, Carmine ;
Alessi, Francesca ;
Pilotto, Silvy ;
Baldi, Eleonora ;
Caniatti, Luisa M. ;
Trentini, Alessandro ;
Casetta, Ilaria ;
Granieri, Enrico ;
Pugliatti, Maura ;
Fainardi, Enrico ;
Bellini, Tiziana .
FLUIDS AND BARRIERS OF THE CNS, 2020, 17 (01)
[9]   Magnetic Resonance Imaging of Blood-Brain Barrier permeability in Dementia [J].
Chagnot, Audrey ;
Barnes, Samuel R. ;
Montagne, Axel .
NEUROSCIENCE, 2021, 474 :14-29
[10]   Is it appropriate to use albumin CSF/plasma ratio to assess blood brain barrier permeability? [J].
Chen, Ruo-Li .
NEUROBIOLOGY OF AGING, 2011, 32 (07) :1338-1339